Announcements Trials
Browse Landscape

Phase

Phase 1/2 11Phase 2 10Phase 1 10Phase 2/3 5Phase 3 3Phase NA 1Phase 4 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 4Other hematologic neoplasm 3Myeloid 3Lymphoid 3Thoracic 1Sarcoma 1Plasma cell 1Head & Neck 1

Conditions

Lymphoma, Follicular 200Lymphoma 199Lymphoma, Non-Hodgkin 167Leukemia, Lymphocytic, Chronic, B-Cell 166Lymphoma, Large B-Cell, Diffuse 163Precursor Cell Lymphoblastic Leukemia-Lymphoma 154Leukemia 89Hodgkin Disease 89Lymphoma, Mantle-Cell 80Lymphoma, B-Cell, Marginal Zone 66Burkitt Lymphoma 65Leukemia, Myeloid, Acute 55Multiple Myeloma 52Lymphoma, Large-Cell, Immunoblastic 48Recurrence 44Neoplasms 38Myelodysplastic Syndromes 38Lymphoma, T-Cell, Cutaneous 36Mycosis Fungoides 30Lymphoma, Large-Cell, Anaplastic 30Waldenstrom Macroglobulinemia 28Leukemia, Myeloid, Chronic-Phase 28Myeloproliferative Disorders 27Lymphoma, B-Cell 27Leukemia, Myeloid, Accelerated Phase 27Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 26Sezary Syndrome 25Leukemia, Biphenotypic, Acute 25Blast Crisis 24Primary Myelofibrosis 22

Interventions

ponatinib 1ibritumomab tiuxetan 1Vorinostat 1Rituximab 1Melphalan 1Imatinib Mesylate 1Etoposide 1Cytarabine 1Carmustine 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Neoplasms by Histologic Type × Lymphoid × Clear all
NCT00773747 2021-04-30

Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)

Merck Sharp & Dohme LLC

Phase 3 Completed
637 enrolled 15 charts
LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT02366663 2018-03-12

SPINOZA

City of Hope Medical Center

Phase 3 Terminated
3 enrolled 8 charts
Lymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT01650805 2014-11-17

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Ariad Pharmaceuticals

Phase 3 Terminated
307 enrolled 11 charts
LymphoidMyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Myeloid, Lymphatic Diseases, Lymphoproliferative Disorders, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡